1. Home
  2. KURA vs EMBC Comparison

KURA vs EMBC Comparison

Compare KURA & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Oncology Inc.

KURA

Kura Oncology Inc.

HOLD

Current Price

$8.99

Market Cap

830.1M

Sector

Health Care

ML Signal

HOLD

Logo Embecta Corp.

EMBC

Embecta Corp.

HOLD

Current Price

$12.14

Market Cap

755.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KURA
EMBC
Founded
2014
1924
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
830.1M
755.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KURA
EMBC
Price
$8.99
$12.14
Analyst Decision
Buy
Buy
Analyst Count
10
2
Target Price
$26.88
$18.50
AVG Volume (30 Days)
1.4M
447.3K
Earning Date
02-25-2026
02-05-2026
Dividend Yield
N/A
4.97%
EPS Growth
N/A
20.90
EPS
N/A
1.62
Revenue
$104,029,000.00
$1,080,400,000.00
Revenue This Year
$109.64
$2.00
Revenue Next Year
$62.82
$0.27
P/E Ratio
N/A
$7.46
Revenue Growth
N/A
N/A
52 Week Low
$5.41
$9.20
52 Week High
$12.49
$19.67

Technical Indicators

Market Signals
Indicator
KURA
EMBC
Relative Strength Index (RSI) 40.65 45.21
Support Level $8.13 $12.01
Resistance Level $9.43 $13.03
Average True Range (ATR) 0.49 0.45
MACD -0.07 0.01
Stochastic Oscillator 36.42 46.06

Price Performance

Historical Comparison
KURA
EMBC

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: